1.  Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1–12.
2.  Centers for Disease Control and Prevention (CDC). Home. Vaccines for Children Program (VFC)
Web site. http://www.cdc.gov/vaccines/programs/
vfc/index.html. Updated April 24, 2014. Accessed
March 2, 2016.
3.  Centers for Disease Control and Prevention (CDC).
About VFC. Vaccines for Children Program (VFC)
Web site. http://www.cdc.gov/vaccines/programs/
vfc/about/index.html. Updated February 14, 2014. Accessed March 2, 2016.
4.  Centers for Disease Control and Prevention (CDC). VFC Detailed Questions and Answers for Parents. Vaccines for Children Program (VFC) Web site. http://www.cdc.gov/vaccines/programs/vfc/parents/
qa-detailed.html. Updated February 19, 2013. Accessed March 2, 2016.

Indication

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Selected Safety Information for ProQuad® (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

ProQuad is contraindicated in individuals with any of the following: history of anaphylactic reaction to neomycin or hypersensitivity to gelatin or any other component of the vaccine; primary or acquired immunodeficiency states; family history of congenital or hereditary immunodeficiency; immunosuppressive therapy; active untreated tuberculosis or febrile illness (>101.3°F or >38.5°C); or those who are pregnant.

Administration of ProQuad (dose 1) to children 12 to 23 months old who have not been previously vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections, is associated with higher rates of fever and febrile seizures at 5 to 12 days after vaccination when compared to children vaccinated with dose 1 of both M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) and VARIVAX® (Varicella Virus Vaccine Live) administered separately.

Use caution when administering ProQuad to children with: a history of cerebral injury or seizures or any other condition in which stress due to fever should be avoided; anaphylaxis or immediate hypersensitivity to eggs; contact hypersensitivity to neomycin; thrombocytopenia.

Advise vaccinees to avoid: close contact with high-risk individuals susceptible to varicella; pregnancy for 3 months after vaccination; using salicylates for 6 weeks after vaccination. Defer vaccination for at least 3 months following blood or plasma transfusions, or administration of immune globulins (IG).

The most frequent vaccine-related adverse events reported in ≥5% of subjects vaccinated with ProQuad were: injection-site reactions (pain/tenderness/soreness, erythema, and swelling); fever; and irritability. Systemic vaccine-related adverse events that were reported at a significantly greater rate in recipients of ProQuad than in recipients of the component vaccines administered concomitantly were fever and measles-like rash.

Before administering ProQuad® (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), please read the Prescribing Information.

Selected Safety Information

Selected Safety Information for ProQuad® (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

ProQuad is contraindicated in individuals with any of the following: history of anaphylactic reaction to neomycin or hypersensitivity to gelatin or any other component of the vaccine; primary or acquired immunodeficiency states; family history of congenital or hereditary immunodeficiency; immunosuppressive therapy; active untreated tuberculosis or febrile illness (>101.3°F or >38.5°C); or those who are pregnant.

Administration of ProQuad (dose 1) to children 12 to 23 months old who have not been previously vaccinated against measles, mumps, rubella, or varicella, nor had a history of the wild-type infections, is associated with higher rates of fever and febrile seizures at 5 to 12 days after vaccination when compared to children vaccinated with dose 1 of both M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) and VARIVAX® (Varicella Virus Vaccine Live) administered separately.

Use caution when administering ProQuad to children with: a history of cerebral injury or seizures or any other condition in which stress due to fever should be avoided; anaphylaxis or immediate hypersensitivity to eggs; contact hypersensitivity to neomycin; thrombocytopenia.

Advise vaccinees to avoid: close contact with high-risk individuals susceptible to varicella; pregnancy for 3 months after vaccination; using salicylates for 6 weeks after vaccination. Defer vaccination for at least 3 months following blood or plasma transfusions, or administration of immune globulins (IG).

The most frequent vaccine-related adverse events reported in ≥5% of subjects vaccinated with ProQuad were: injection-site reactions (pain/tenderness/soreness, erythema, and swelling); fever; and irritability. Systemic vaccine-related adverse events that were reported at a significantly greater rate in recipients of ProQuad than in recipients of the component vaccines administered concomitantly were fever and measles-like rash.

Before administering ProQuad® (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), please read the Prescribing Information.

VACC-1175000-0002 02/17